NEW YORK and CAESAREA, Israel, Sept.
18, 2019 /PRNewswire/ -- DarioHealth
Corp. ("DarioHealth" or "Dario") (Nasdaq: DRIO), a
leading, global digital therapeutics company, today announced that
it has received a notice of allowance from the U.S. Patent and
Trademark Office titled "Systems and Methods for Enabling Optical
Transmission of Data Between a Sensor and a Smart Device." The
patent will allow Dario to develop paired smartphone devices that
can collect and analyze real-time medical data and provide
immediate and highly detailed, personalized data reports to the
user. Once collected, this data can be shared with healthcare
providers through the DarioEngage™ platform to facilitate digital
health interventions based on the data analysis.
"Dario's business and product strategy is guided by evidence
that shows that increased user engagement and direct empowerment of
individuals to manage their personal health leads to better medical
outcomes," said Erez Raphael, DarioHealth's chief executive
officer. "As a result, our product innovation has continually
focused on enhancing Dario's user experience and developing new
ways to integrate intelligent, medical device technology with the
smartphone to make health and chronic condition management easy,
affordable and convenient."
DarioHealth's digital therapeutics solutions are unique in that
they capture and analyze members' real-time, clinical data using a
member's smartphone and allow for full access and connectivity to
that data at any time throughout the day, along with personalized
daily and weekly health data reports. This provides Dario members a
fully personalized, integrated and exceptionally convenient
platform to manage their health throughout the day, and facilitates
a heightened user experience, increased user engagement and
improved clinical health outcomes.
As the future of healthcare becomes increasingly digitized and
focused on empowering individuals to take control of their personal
health, DarioHealth believes smartphones will serve as the primary
conduit for health interventions and chronic condition
management.
As a pioneer in the digital therapeutics industry,
DarioHealth supports the evolution of iOS and Android mobile
devices and continually seeks opportunities to use smartphones as
the primary health management device, integrated with connected
medical devices, rather than requiring users to purchase and use a
secondary device that has to synchronize information with a
smartphone, which is less convenient, effective and efficient.
DarioHealth plans to begin development of new paired smartphone
medical devices in the coming year, which will further advance the
company's objective of providing highly effective, inexpensive and
convenient digital therapeutic health solutions that empower
individuals to best manage their chronic health conditions and
improve their overall health.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading, global digital
therapeutics company revolutionizing the way people with
chronic conditions manage their health. By delivering
evidence-based interventions that are driven by data, high-quality
software and coaching, we empower individuals to make healthy
adjustments to their daily lifestyle choices to improve their
overall health. Our cross-functional team operates at the
intersection of life sciences, behavioral science and software
technology to deliver highly engaging therapeutic interventions.
Dario is one of the highest-rated diabetes solutions in the market,
and its user-centric MyDario™ mobile app is loved by tens of
thousands of consumers around the globe. DarioHealth is rapidly
moving into new chronic conditions and geographic markets, using a
performance-based approach to improve the health of users managing
chronic disease. To learn more about DarioHealth and its digital
health solutions, please go to: http://mydario.com/
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company discusses
its belief that smartphones will serve as the primary conduit for
health interventions and chronic condition management and its plans
to begin development of new paired smartphone medical devices in
the coming year, which will further advance the company's objective
of providing highly effective, inexpensive and convenient digital
therapeutic health solutions that empower individuals to best
manage their chronic health conditions and improve their overall
health, it is using forward-looking statements. Readers are
cautioned that certain important factors may affect the Company's
actual results and could cause such results to differ materially
from any forward-looking statements that may be made in this news
release. Factors that may affect the Company's results include, but
are not limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Corporate Contact:
Claudia
Levi
Content & Communications Manager
claudia@mydario.com
+1-347-767-4220
Media Inquiries:
Catherine
Polisi Jones
Polisi Jones Communications
cjones@polisijones.com
+1-917-330-8934
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dariohealth-awarded-us-patent-for-optical-transmission-of-data-between-a-sensor-and-smart-device-300920682.html
SOURCE DarioHealth Corp.